Studies on Combined Experimental Antitumor Drug Therapy. An Attempt to Overcoming the Natural Drug Resistance

Abstract

Modern drug therapy of cancer patients is mainly combined. The possibilities of using a new non-myelo-and non-immuno-suppressive antitumor drug of natural origin, Thaliblastine (TBL)

Antileukemic Activity of Epirubicin Conjugated with Biopolymer Dextran Against Lymphoid Leukemia L1210 as Tumor Model

“…Our in vivo studies were performed in male hybrid BDF 1 mice. The antileukemic activity was studied on ascitic lymphoid L1210 leukemia, with transplantation dose of 1x10 5 tumor cells/mouse, on day 0, intraperitoneally (i. p.). Epirubicin (commercial antitumor drug Farmorubicin, Farmacia) and its original conjugate with dextran were introduced intraperitoneally, once a day, on day 1, day 4 and day 8 after the tumor transplant.…”

“…Their clinical effectiveness is limited by the development of multidrug resistance (MDR) (1,2). This problem is crucial for patients, because the tumor cells become resistant not only to drug used during cancer treatment, but also to many other drugs that are structurally and functionally unrelated (3,4,5). The anthracycline derivative epirubicin is one of the most effective antitumor drugs in the treatment of various types of solid tumors.…”

Antimetastatic Activity of the Novel Spin-Labeled Nitrosourea Derivative SLNU on Spontaneous Lung Metastases of the Lewis Lung Carcinoma

“…The detailed preclinical studies of SLNU as a potential novel nitrosourea antitumor drug are in progress in the Laboratory of Oncopharmacology, National Oncological Center in Sofia and in other institutes. This work is a part of our extended systemic investigations on the preclinical oncopharmacology of novel and known nitrosourea derivatives, including new approaches to improvement of their antitumor and antimetastatic effects, with possible clinical transfer (6,7,8,9,10).…”